HC Wainwright set a $10.00 price objective on Axsome Therapeutics (NASDAQ:AXSM) in a research report report published on Wednesday. The brokerage currently has a buy rating on the stock.
A number of other equities research analysts also recently weighed in on AXSM. Zacks Investment Research downgraded shares of Axsome Therapeutics from a hold rating to a sell rating in a research note on Wednesday, August 15th. LADENBURG THALM/SH SH set a $5.00 target price on shares of Axsome Therapeutics and gave the company a buy rating in a research note on Wednesday, October 17th. ValuEngine raised shares of Axsome Therapeutics from a hold rating to a buy rating in a research note on Wednesday, November 7th. Finally, Cantor Fitzgerald assumed coverage on shares of Axsome Therapeutics in a research note on Thursday, November 15th. They issued an overweight rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $10.70.
Shares of AXSM opened at $3.20 on Wednesday. The company has a market capitalization of $95.40 million, a P/E ratio of -2.58 and a beta of -0.57. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 6.00. Axsome Therapeutics has a 1-year low of $2.05 and a 1-year high of $5.95.
Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Friday, November 9th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. On average, analysts anticipate that Axsome Therapeutics will post -1.13 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of AXSM. Alethea Capital Management LLC raised its stake in shares of Axsome Therapeutics by 102.1% during the third quarter. Alethea Capital Management LLC now owns 547,443 shares of the company’s stock worth $1,889,000 after acquiring an additional 276,620 shares in the last quarter. Sio Capital Management LLC raised its stake in shares of Axsome Therapeutics by 115.5% during the third quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock worth $1,437,000 after acquiring an additional 223,168 shares in the last quarter. Finally, Worth Venture Partners LLC purchased a new position in shares of Axsome Therapeutics during the third quarter worth approximately $138,000. 11.85% of the stock is currently owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Featured Article: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.